Vericiguat

CHEMBL4066936 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

426.4 g/mol

LogP

1.5

Phase

4

Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator that directly activates sGC independent of nitric oxide (NO) availability and sensitizes sGC to low levels of NO, increasing cyclic GMP (cGMP) production in vascular smooth muscle and cardiomyocytes. It is approved for reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event. Increased cGMP mediates vasodilation, reduced cardiac afterload, and cardioprotective signaling.

분자량

426.4000 g/mol

LogP

1.50

TPSA

147.00 Å²

리핀스키 5의 법칙

통과

치료 영역

Cardiovascular Disease Obesity Hypertension Breast Cancer Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N

InChI

InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)

Molecular Formula

C19H16F2N8O2

HBD / HBA

3 / 10

회전 가능 결합

5

무거운 원자

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator that directly activates sGC independent of nitric oxide (NO) availability and sensitizes sGC to low levels of NO, increasing cyclic GMP (cGMP) production in vascular smooth muscle and cardiomyocytes. It is approved for reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event. Increased cGMP mediates vasodilation, reduced cardiac afterload, and cardioprotective signaling.

Yes, Vericiguat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4066936. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 54674461. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Vericiguat PillFYI에서

구조

핵심 데이터

분자식: C19H16F2N8O2
동의어: 1

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.